Download  full announcement   Renalytix AI plc  (LSE: RENX), a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that results from a

Download  full announcement Renalytix AI plc (LSE: RENX), a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that it has yesterday

Download  full announcement Renalytix AI plc (LSE: RENX), a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that its wholly-owned

Download  full announcement Renalytix AI plc (LSE: RENX), a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that it has confidentially

Download  full announcement Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that at the general meeting of the Company held today the resolution to cancel the share premium account of the Company and

Download  full announcement Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence  in vitro  diagnostics for kidney disease, announces  that, following legal advice, it has taken the decision to remove the offering restrictions imposed by US securities law

Download  full announcement Proposed capital reduction and notice of General Meeting Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence  in vitro  diagnostics for kidney disease, announces that a circular (a “Circular”) will today be sent to

NEW YORK, April 27, 2020 /PRNewswire/ --  Renalytix AI plc  (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence  in vitro  diagnostics for kidney disease, announced  today  that it has received ISO 13485:2016 certification for its development and commercial laboratory

Download  full announcement Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence  in vitro  diagnostics for kidney disease, announces  that the  KidneyIntelX ™  platform will be used by investigators from the Icahn School of Medicine at Mount Sinai to

Download  full announcement Agreement with Three Rivers Provider Network, the fastest growing US proprietary provider network KidneyIntelX   risk assessment testing now available to Three Rivers members and clients Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial